cqvip:Objectives-To evaluate prescription practices and response to infliximab treatment for Crohn’s disease(CD).Patients and methods-The files of CD patients treated with at least one infusion of infliximab treated in gastroenterology units belonging to university teaching hospitals of the Parisian hospitals group(Assistance Publique-Hpitaux de Paris(AP-HP))during the year 2000 were analyzed retrospectively.Results-One hundred and thirty-seven patients(36.0 ±12.7 years,92 females)from 12 centers were studied.Indication for treatment was fistulae or perianal disease in 39%of patients,active Crohn’s disease in 45and mixed conditions in 16%.Mean follow-up was 15.2 ±7.2 months.The overall response rate was 85%.No predictive factor of sustained remission could be identified.The mean time to relapse was to 3.9 ±3.1 months.Thirty-eight patients were on maintenance therapy at the end of the follow-up;37%exhibiting progressive lost of response to treatment.Immunosuppressive therapy was added to infliximab in 78%of cases but response to infliximab was not modified by addition of immunosuppressive drugs.Adverse events,most frequently minor,were noted in 23%of the patients.Conclusion-This retrospective study confirms the efficacy and safety of infliximab in CD.
展开▼
